Onconetix, Inc. goes into tomorrow's earnings release carrying a freshly rebuilt short position, a 63% monthly price collapse, and a cost to borrow that would make most traders wince.
The defining move this week was in short interest. It has climbed back to roughly 25% of the free float — up from near-zero on May 4, when barely 2,200 shares were estimated short. That rebuilding happened fast: within four sessions, the short position had grown to over 160,000 shares, pushing the float-adjusted ratio to a level that places ONCO well above the typical small-cap biotech. The ORTEX short score reads 61.3, down modestly from a high of 79.7 at end of April when the previous short wave was at its peak — a sign that the current rebuild, while sharp, has not yet reached that earlier extreme. Days-to-cover ranks in the 97th percentile of the universe, meaning the position would take an unusually long time to unwind relative to normal trading volume.
The borrow market tells a complementary story, though with an important nuance. Borrowing ONCO shares costs 313% annualised — a level that has nonetheless fallen sharply from above 500% in mid-April and over 600% in early April, as the extreme prior squeeze in the lending pool has eased. Availability is extremely loose right now: utilisation has dropped to just 1.3%, down from a 52-week high of 98.6%. That means shares to borrow are plentiful relative to the current short position — new shorts face no supply constraint, even if the cost remains painful by any normal standard. This combination of high cost but loose availability is characteristic of a stock where lenders have pulled back hard on fees but fresh demand has not yet absorbed the supply.
The price chart frames the urgency. ONCO is down 63% over the past month to $0.41. The stock shed 22% in the past week alone, clawing back just 1.4% on Tuesday. Close peers have also sold off — ADTX lost 36% on the week and NCNA fell 15% — suggesting sector pressure, but ONCO's drawdown is considerably sharper than the peer group. No analyst coverage data is available, and the negative enterprise value recorded in the data flags the degree of balance-sheet stress already priced in by the market.
The only institutional activity worth noting is from HRT Financial LP, the 10% owner, which has been trading actively through April — selling 49,710 shares on April 21 and 94,462 shares on April 20 at around $0.69-0.75, while also buying aggressively on April 14 and 15 at $0.76-0.77. The net direction across the visible window is net selling, though the scale of individual transactions is relatively modest in dollar terms (the largest single sale was $70,847). No c-suite insider buying has appeared in recent data, and stock award grants from December 2024 are the only executive-level transactions on record.
Earnings history adds another layer of caution. The last four reported events have produced moves of +12%, -10%, +0.9%, and -17% on the day, with the five-day reaction typically amplifying the initial direction — the most recent full-week reaction was -35% after the March 25 print. Tomorrow's release (after market, May 14) is therefore the next hard catalyst, and the combination of a heavily rebuilt short position, a stock already down 63% on the month, and a borrow cost that discourages holding shorts for long sets up a binary outcome where the speed of any move is as important as its direction.
See the live data behind this article on ORTEX.
Open ONCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
